<DOC>
	<DOC>NCT01705249</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this study is to investigate the bleeding profile after switch from Trisekvens速 to Activelle速 (1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)).</brief_summary>
	<brief_title>Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle速 in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy women At least 3 months on Trisekvens速 before screening period Ability to understand and comply with the protocol requirements Less than 12 months or more than 36 months postmenopausal judged by the Investigator Known, suspected, or past history of hormone dependent tumor/cancers Deep venous thrombosis, active thrombophlebitis, thromboembolic disorders, cerebrovascular accidents or past history of these conditions Ischemic heart disease or myocardial infarction within 6 months prior to randomization</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>